Compounds > sdz 33-243

Page last updated: 2024-12-08

sdz 33-243

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

SDZ 33-243: cpd is non-immunosuppressive [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	15161762
CHEMBL ID	4475833
MeSH ID	M0180588

Synonyms (7)

Synonym
sdz 33-243
acetyl cyclosporin a
CHEMBL4475833
o-acetyl cyclosporin
KUSICUWKCBCAHV-ZSINMPTNSA-N
xxxlvlaalla;b 3-243; o-acetyl-c91-cyclosporin a; o-acetylcyclosporin a
[(e,1r,2r)-1-[(2s,5s,11s,14s,17s,20s,23r,26s,29s,32s)-5-ethyl-1,7,10,16,20,23,25,28,31-nonamethyl-11,17,26,29-tetrakis(2-methylpropyl)-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-14,32-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacont-2-y

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay ID	Title	Year	Journal	Article
AID1532162	1,9-decadiene/aqueous buffer solution partition coefficient, log D of the compound in PBS at pH 7.4 by shake flask method	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
AID1532161	Thermodynamic aqueous solubility of compound in pH 7.4 PBS by UPLC-MS analysis	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (80.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (20.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
putrescine [no description available]	1.98	1	0	alkane-alpha,omega-diamine	antioxidant; fundamental metabolite
spermidine [no description available]	1.98	1	0	polyazaalkane; triamine	autophagy inducer; fundamental metabolite; geroprotector
spermine [no description available]	1.98	1	0	polyazaalkane; tetramine	antioxidant; fundamental metabolite; immunosuppressive agent
eflornithine Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.	1.98	1	0	alpha-amino acid; fluoroamino acid	trypanocidal drug
thiazoles [no description available]	1.97	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	2.17	1	0	cyclic ketone; erythromycin
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	1.97	1	0	pseudohalide anion	mitochondrial respiratory-chain inhibitor
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	1.97	1	0	organic bromide salt	colorimetric reagent; dye
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	2.17	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	1.97	1	0
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	2.17	1	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
azidopine azidopine: structure given in first source	1.97	1	0	benzamides
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	1.97	1	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	2.17	1	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
cyclosporin c [no description available]	2.17	1	0
overall Overall: A single citation covering papers or abstracts presented at a meeting. The publication type may be used for a single citation with or without the additional indexing or cataloging of individual papers. The individual papers, however, are not labeled OVERALL.. (Z)-roxithromycin : A minor geometrical isomer of roxithromycin.	2.17	1	0	roxithromycin
cyclosporin h cyclosporin H: non-immunophilin-binding cyclosporin; RN given for (D)-Val	2.17	1	0
isocyclosporin a isocyclosporin A: structural analog of cyclosporin A	2.17	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	1.98	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Carcinoma, Oat Cell [description not available]	0	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	0	1.98	1	0
Carcinoma, Non-Small Cell Lung [description not available]	0	1.98	1	0
Cancer of Lung [description not available]	0	1.98	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	0	1.98	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	1.98	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	1.98	1	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	0	1.98	1	0